XML 35 R14.htm IDEA: XBRL DOCUMENT v3.20.2
- INCOME TAXES
6 Months Ended
Jul. 31, 2020
- INCOME TAXES [Abstract]  
- INCOME TAXES

Note 8 - INCOME TAXES

 

The Company adopted the provisions of uncertain tax positions as addressed in ASC 740-10-65-1. As a result of the implementation of ASC 740-10-65-1, the Company recognized no increase in the liability for unrecognized tax benefits. As of July 31, 2020, the Company had net operating loss carry forwards of $130,256 that may be available to reduce future years' taxable income in varying amounts through 2041. Future tax benefits which may arise as a result of these losses have not been recognized in these financial statements, as their realization is determined not likely to occur and accordingly, the Company has recorded a valuation allowance for the deferred tax asset relating to these tax loss carry-forwards.

 

The valuation allowance at July 31, 2020 was $27,354. The net change in valuation allowance during the six months ended July 31, 2020 was $22, 756. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. 

 

 

The provision for Federal income tax consists of the following: 

 

 

 

 

 

July 31, 2020

 

January 31, 2020

Non-current deferred tax assets

 

 

$

                        -

$

                        -

Net-operating loss carry forwards

 

 

 

               27,354

 

                 4,598

Valuation allowance

 

 

 

               (27,354)

 

         (4,598)

 

 

 

 

 

 

 

Net-deferred tax assets

 

 

$

                        -

$

                        -

 

 VITASPRING BIOMEDICAL CO. LTD.

Six months ended July 31, 2020 and 2019

Notes to the Financial Statements

(Unaudited)

 

 

The actual tax benefit at the expected rate of 21% differs from the expected tax benefit for the six months ended July 31, 2020 are as follows:

 

 

 

 

 

July 31, 2020

 

January 31, 2020

Computed “expected tax expense (benefit)

 

 

$

             (22,756)

$

(1,453)

Change in valuation allowance

 

 

 

                22,756

 

                   1,453

 

 

 

 

 

 

 

Actual tax expense (benefit)

 

 

$

                         -

$

                         -